Short Sellers Can’t Make Up Their Minds on Major Biotechs

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Short Sellers Can’t Make Up Their Minds on Major Biotechs

© Thinkstock

The short interest data are out for the most recent settlement date, October 14. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

As we have said before, FDA rulings can make or break the biotech sector, and short sellers and mega-bulls often go to war against each other in these companies. After all, if a single failed clinical trial can mean disaster for a stock, then some short sellers can argue for a stock implosion down the road.

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.

Amgen Inc. (NASDAQ: AMGN) saw its short interest decrease to 7.91 million shares from the previous level of 8.30 million. Shares closed most recently at $157.90, in a 52-week trading range of $139.02 to $176.85.

[nativounit]

Biogen Inc. (NASDAQ: BIIB) had its short interest increase slightly to 2.55 million shares from the previous 2.45 million. The stock closed Tuesday at $286.00, within a 52-week range of $223.02 to $333.65.

Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 8.99 million shares from the previous 8.15 million. Shares closed most recently at $97.63, in a 52-week range of $93.05 to $128.39.

Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest increase to 14.84 million shares from 13.24 million in the previous period. Shares closed Tuesday at $74.41, in a 52-week trading range of $72.21 to $111.11.

MannKind Corp. (NASDAQ: MNKD) saw the number of its shares short decrease to 97.76 million. The previous reading was 99.70 million. The stock closed most recently at $0.52, in a 52-week range of $0.44 to $3.79. Note that MannKind is one of the most shorted Nasdaq stocks.

Alexion Pharmaceuticals Inc.’s (NASDAQ: ALXN) short interest decreased to 5.37 million, compared to the previous level of 5.58 million. Shares closed most recently at $121.41, in a 52-week range of $110.56 to $193.45.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618